Elizabeth G. Nabel
CIK: 0001619929
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jun 10, 2026LYEL
Lyell Immunopharma, Inc.
Award(A)DirectOption (right to buy)
9.3K shares- - May 6, 2026MRNA
Moderna, Inc.
Award(A)DirectRestricted Stock Units
8.4K shares- - Apr 30, 2026MRNA
Moderna, Inc.
Exercise(M)Direct16.2K shares- - Apr 28, 2026MDT
Medtronic plc
Tax Payment(F)Direct207 shares at avg. $81.90$17K - Apr 27, 2026MDT
Medtronic plc
Award(A)Direct2.1K shares- - May 15, 2025LYEL
Lyell Immunopharma, Inc.
Award(A)DirectOption (right to buy)
130K shares- - Apr 30, 2025MRNA
Moderna, Inc.
Award(A)DirectRestricted Stock Units
16.2K shares- - Apr 30, 2025MRNA
Moderna, Inc.
Exercise(M)Direct979 shares- - Apr 29, 2025MDT
Medtronic plc
Tax Payment(F)Direct216 shares at avg. $84.60$18K - Apr 28, 2025MDT
Medtronic plc
Award(A)Direct2.1K shares at avg. $84.04$175K - Apr 8, 2025ACCD
Accolade, Inc.
Disposition(D)Direct42K shares at avg. $7.03$295K - Mar 3, 2025ACCD
Accolade, Inc.
Award(A)DirectRestricted Stock Units
12.5K shares- - Feb 28, 2025ACCD
Accolade, Inc.
Exercise(M)Direct2.2K shares- - Dec 2, 2024ACCD
Accolade, Inc.
Exercise(M)Direct2.2K shares- - Sep 3, 2024ACCD
Accolade, Inc.
Exercise(M)Direct2.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 10, 2026 |  LYEL Lyell Immunopharma, Inc. | Award(A) Option (right to buy) | 9,250 | - | - | Direct |
| May 6, 2026 |  MRNA Moderna, Inc. | Award(A) Restricted Stock Units | 8,371 | - | - | Direct |
| Apr 30, 2026 | MRNA Moderna, Inc. | Exercise(M) | 16,233 | - | $0 | Direct |
| Apr 28, 2026 |  MDT Medtronic plc | Tax Payment(F) | 207 | $81.90 | $16,953 | Direct |
| Apr 27, 2026 | MDT Medtronic plc | Award(A) | 2,111 | - | $0 | Direct |
| May 15, 2025 | LYEL Lyell Immunopharma, Inc. | Award(A) Option (right to buy) | 130,000 | - | - | Direct |
| Apr 30, 2025 | MRNA Moderna, Inc. | Award(A) Restricted Stock Units | 16,233 | - | - | Direct |
| Apr 30, 2025 | MRNA Moderna, Inc. | Exercise(M) | 979 | - | - | Direct |
| Apr 29, 2025 | MDT Medtronic plc | Tax Payment(F) | 216 | $84.60 | $18,274 | Direct |
| Apr 28, 2025 | MDT Medtronic plc | Award(A) | 2,083 | $84.04 | $175,055 | Direct |
| Apr 8, 2025 |  ACCD Accolade, Inc. | Disposition(D) | 41,982 | $7.03 | $295,133 | Direct |
| Mar 3, 2025 | ACCD Accolade, Inc. | Award(A) Restricted Stock Units | 12,489 | - | - | Direct |
| Feb 28, 2025 | ACCD Accolade, Inc. | Exercise(M) | 2,178 | - | - | Direct |
| Dec 2, 2024 | ACCD Accolade, Inc. | Exercise(M) | 2,179 | - | $0 | Direct |
| Sep 3, 2024 | ACCD Accolade, Inc. | Exercise(M) | 2,179 | - | $0 | Direct |
1-15 of 15 transactions
About NABEL ELIZABETH G
NABEL ELIZABETH G (SEC CIK 0001619929) files insider reports with the SEC as Director of Lyell Immunopharma, Inc. (LYEL), Director of Moderna, Inc. (MRNA) and Director of Medtronic plc (MDT). Signal8 also holds filings tied to 1 other company.
Signal8 holds 12 ownership filings by NABEL ELIZABETH G, all Form 4s, filed between Sep 5, 2024 and Jun 12, 2026. Those filings report 15 transactions, from Sep 3, 2024 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on NABEL ELIZABETH G's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by NABEL ELIZABETH G
- Jun 10, 2026: Grant or award of LYEL derivative securities (Form 4, code A).
- May 6, 2026: Grant or award of MRNA derivative securities (Form 4, code A).
- Apr 30, 2026: Option exercise of MRNA shares (Form 4, code M).
- Apr 28, 2026: Tax withholding of MDT shares (Form 4, code F).
- Apr 27, 2026: Grant or award of MDT shares (Form 4, code A).
Other insiders filing for Lyell Immunopharma, Inc. (LYEL)
- Aguirre Jarrad Mattieu, Chief Medical Officer
- Shook David, Chief Medical Officer
- Seely Lynn, President and CEO
- Hill Stephen J., Chief Operating Officer
- Lee Gary K., Chief Scientific Officer
- Bulis Veronica Sanchez, VP, Corporate Controller